Corcept Therapeutics (CORT) Common Equity (2010 - 2026)
Corcept Therapeutics (CORT) posted Common Equity of $705.8 million for Q2 2026, up 10.63% sequentially from $638.0 million in Q1 2026, and up 11.01% YoY from $635.8 million in Q2 2025.
Corcept Therapeutics (CORT) Common Equity (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Common Equity for 17 years, with the latest figure at $705.8 million in Q2 2026.
- Quarterly Common Equity rose 11.01% year-over-year to $705.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $705.8 million (up 11.01% YoY) and the FY2025 annual result came in at $647.8 million, down 4.68% from the prior year.
- Common Equity advanced to $705.8 million in Q2 2026 per CORT's latest filing, from $638.0 million in the prior quarter.
- Over five years, Common Equity peaked at $705.8 million in Q2 2026 and troughed at $407.8 million in Q1 2022.
- A 5-year average of $563.9 million and a median of $572.1 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity slipped 20.16% in 2022, then soared 41.42% in 2024.
- Over 5 years, Common Equity stood at $501.8 million in 2022, then advanced by 0.97% to $506.7 million in 2023, then jumped by 34.12% to $679.6 million in 2024, then fell by 4.68% to $647.8 million in 2025, then rose by 8.95% to $705.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $705.8 million, $638.0 million, and $647.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 705.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 705.78 Mn |
| Mar 31, 2026 | 637.99 Mn |
| Dec 31, 2025 | 647.81 Mn |
| Sep 30, 2025 | 631.90 Mn |
| Jun 30, 2025 | 635.79 Mn |
| Mar 31, 2025 | 683.29 Mn |
| Dec 31, 2024 | 679.59 Mn |
| Sep 30, 2024 | 638.84 Mn |
| Jun 30, 2024 | 596.24 Mn |
| Mar 31, 2024 | 547.86 Mn |
| Dec 31, 2023 | 506.71 Mn |
| Sep 30, 2023 | 461.68 Mn |
| Jun 30, 2023 | 421.61 Mn |
| Mar 31, 2023 | 529.58 Mn |
| Dec 31, 2022 | 501.84 Mn |
| Sep 30, 2022 | 473.36 Mn |
| Jun 30, 2022 | 442.33 Mn |
| Mar 31, 2022 | 407.81 Mn |
| Dec 31, 2021 | 375.81 Mn |
| Sep 30, 2021 | 540.23 Mn |